CD3 + lymphocytes or CD20 + lymphocytes as assessed by western blot (Fig. 2a-d and Supplementary Fig. 2 online) and immunoassay ( Fig. 2e,f) . Moreover, CathL was also highly expressed in stem-cell antigen 1-positive (Sca-1 + ) subpopulations of bone marrow-derived progenitor cells that have been shown to augment neovascularization ( Supplementary Fig. 2 online) . The enzymatic activity of CathL was significantly (P < 0.05) higher in EPC as compared to HUVEC and CD14 + monocytes (Fig. 2g) , whereas CathD activity was only slightly higher in EPC, despite higher mRNA expression levels (data not shown). The observed high activity of CathL in EPC may be in part the result of strong expression of the p41 splice variant (p41(65aa)) of the major histocompatibility complex class II-associated invariant chain ( Fig. 2h and Supplementary Methods online), as this protein is known to bind to CathL and to help maintain the pool of mature activated CathL even at a neutral pH 17 .
Role of CathL in vasculogenesis and angiogenesis
Because CathL activity was specifically increased in EPC, we investigated the functional role of CathL in postnatal neovascularization using a hind limb ischemia model. Genetic ablation of CathL expression caused a significant (P < 0.05) impairment of neovascularization in CathLdeficient (Ctsl -/-) mice (Fig. 3a) , indicating that CathL is critical for ischemia-induced neovascularization.
Vasculogenesis, an important feature of ischemia-induced neovascularization 1 , depends on various critical steps (Fig. 3b) . Because cathepsins exert widespread substrate specificity, and thereby may influence different processes, we determined the potential involvement of CathL in each individual step. First, we assessed the mobilization of stem cells from the bone marrow in wild-type and Ctsl -/-mice. But mobilization induced by hematopoietic growth factors (stem cell factor: 300 µg/kg and granulocyte colony-stimulating factor: 250 µg/kg daily for 3 d) was not impaired in Ctsl -/-mice (wild-type showed a 258.8 ± 37% increase versus Ctsl -/-342.6 ± 65% increase in c-kit + Sca-1 + cells in peripheral blood). Moreover, adhesion of cultivated EPC to different matrices ( Fig. 3c) , to tumor necrosis factor-α-stimulated HUVEC (data not shown), or to denuded arteries in vivo was not modulated by pharmacological inhibition of CathL with Z-FF-FMK (Fig. 3d, Supplementary  Fig. 3 and Supplementary Methods online). Inhibition of CathL in human EPC or genetic ablation using Ctsl -/-cells also did not result in a significant change in proliferation, apoptosis or migration of EPC ( Supplementary  Fig. 3 and Supplementary Methods online). The release of growthpromoting factors from EPC also was similarly not affected by inhibition of CathL (data not shown). Finally, we showed that CathL does not modulate the angiogenic capacity of mature endothelial cells ( Supplementary Fig. 4 and Supplementary Methods online). Thus, our data indicate that CathL is not critically involved in the regulation of EPC mobilization, survival, proliferation, migration or the angiogenic activity of mature endothelial cells.
Because cathepsins are matrix-degrading enzymes, we hypothesized that CathL contributes, instead, to the invasive capacity of EPC. EPC showed a more than twentyfold higher invasive capacity as compared to HUVEC and a significantly (P < 0.05) higher invasion than CD14 + monocytes (Fig. 4a) . Incubation of EPC with the CathL inhibitor significantly (P < 0.05) reduced the cells' invasive capacity (Fig. 4a) . In addition, incubation of EPC with cystatin C, a general inhibitor of papain-like cysteine peptidases (e.g., cathepsins B, H and L), also significantly (P < 0.05) decreased EPC invasiveness, whereas the cathepsin S (CathS)-inhibitor (Z-Phe-Leu-COCHO) 18 , matrix metalloproteinase (MMP) inhibitors (GM6001 for MMP-3, GM1489 for MMP-9) and elastase inhibitors did not ( Fig. 4a and data not shown). A cytotoxic effect of the inhibitors on EPC was excluded by measuring apoptosis and necrosis (data not shown). Moreover, we confirmed that the inhibitor of CathL did not affect MMP-2 and MMP-9 activity in EPC (data not shown).
To identify potential CathL targets involved in permitting EPC invasion, we determined the matrix degradation activity. Because CathL has been shown previously to degrade the matrix components gelatin and collagen 19 , we assessed the proteolytic activity of EPC extracts by zymography. EPC extracts showed high matrix-degrading activity, which was abolished by pharmacological inhibition of CathL (Fig. 4b,c) . Moreover, active CathL as well as CathL inhibitor-sensitive gelatinolytic activities were detected in EPC culture supernatants (Fig. 4d,e, Supplementary Fig. 5 and Supplementary Methods online). Thus, active CathL is secreted by EPC, promoting extracellular degradation of matrix proteins. To determine whether the extracellular matrix proteolytic activity is linked to EPC invasion, we measured the degradation of the quenched fluorescent substrate DQ gelatin in a three-dimensional Matrigel assay. Confocal images showed that invading EPC degraded matrix protein ( Supplementary Fig. 6 online). Extracellular matrix degradation was reduced by the CathL inhibitor ( Supplementary Fig. 6 online) . Similar results were observed using DQ collagen type IV as a substrate (data not shown). The specific requirement of CathL for proteolysis of matrix proteins and invasion was further confirmed by using Ctsl -/-progenitor cells (Fig. 4f,g ). Proteolysis of fluorescence-labeled collagen and gelatin as well as gelatinolytic activity of cell lysates or supernatants were virtually absent in Ctsl -/-cells ( Fig. 4f and Supplementary  Fig. 5 online) . Moreover, the invasive activity of Ctsl -/-Sca-1 + progenitor cells was significantly (P < 0.05) reduced as compared to wild-type cells (Fig. 4g) . These data suggest that CathL is required for the extracellular matrix proteolysis and, subsequently, for the invasive capacity of progenitor cells in culture.
CathL contributes to EPC-mediated neovascularization in vivo
Having shown that CathL specifically affects EPC invasion, we investigated the effect of CathL on vascular integration and function of EPC during neovascularization in vivo. EPC were pretreated ex vivo with Z-FF-FMK or vehicle for 2 h prior to infusion. EPC were intravenously injected 24 h after unilateral induction of hind limb ischemia in nude mice. Mice receiving EPC pretreated with Z-FF-FMK showed significantly (P < 0.01) less improvement in limb perfusion as compared to mice receiving vehicle-treated EPC (Fig. 5a,b) . Consistently, capillary density increased to a greater extent in mice receiving untreated EPC as compared to Z-FF-FMK-treated EPC ( Fig. 5c and Supplementary Fig. 7 online) . In addition, the number of small conductance vessels (<50 µm) was significantly (P < 0.05) increased in mice receiving untreated EPC, whereas Z-FF-FMK-pretreated EPC abrogated this increase ( Supplementary  Fig. 8 online) . Similar findings were obtained with mouse bone marrowderived Lin -Sca-1 + progenitor cells: Z-FF-FMK pretreatment abolished the Lin -Sca-1 + progenitor cell-mediated improvement in neovascularization ( Supplementary Fig. 9 online). Early EPC homing to the site of ischemia was investigated in vivo by magnetic resonance imaging (MRI) after labeling of EPC with iron particles. In the 'turbo inversion recovery magnitude' images, the area of ischemia is visualized by a strong hyperintensity as compared to the contralateral limb (Fig. 5d) . In the T2* images, which were used for the assessment of tissue iron content, homing of untreated EPC after 24 h led to a marked signal extinction (iron artifact), whereas in animals receiving EPC pretreated with Z-FF-FMK, we observed no loss in signal intensity, suggesting a considerable reduction in early EPC homing (Fig. 5d) . Histological analysis of muscle sections harvested on day 14 consistently showed that the incorporation of human EPC into vascular structures was significantly (P < 0.05) reduced in mice receiving EPC pretreated with Z-FF-FMK. Incorporated cells were identified by double staining for human leukocyte antigen or labeling with CM-Dil to detect transplanted human EPC, in combination with the endothelial markers CD146, von Willebrand factor or CD31 (Fig. 5e ,f, Supplementary Methods and Supplementary Fig. 10 online) .
We used intravital fluorescence videomicroscopy to monitor the effects of pretreatment with the CathL inhibitor on homing and incorporation of progenitor cells into tumor vessels (Supplementary Methods online). Within 3 d after infusion, untreated progenitor cells adhered to the endothelium of tumor blood vessels, extravasated into the tumor stroma, began to organize into cord-like structures and incorporated into the tumor microvasculature. In contrast, markedly fewer Z-FF-FMK-pretreated cells successfully extravasated into the tumor tissue and remained in an inactive state, as suggested by their persistent round morphology, lack of tumor stroma invasion and lack of incorporation into the tumor blood vessels ( Supplementary  Fig. 11 online) . Control experiments confirmed that the viability of the Z-FF-FMK-treated cells was not affected (data not shown) and that CathL activity was completely inhibited for at least 48 h following Z-FF-FMK treatment (Supplementary Fig. 3 online) .
We confirmed that CathL is required for the neovascularization capacity of progenitor cells using a gene-based approach. The improvement of neovascularization following hind limb ischemia was significantly (P < 0.01) reduced in mice receiving Ctsl -/-bone marrow-derived cells as compared to mice treated with wild-type cells (Fig. 5g) . Consistently, the increase in capillary density was significantly (P = 0.023) lower in mice treated with Ctsl -/-bone marrow-derived cells (133 ± 16%) as compared to mice treated with wild-type cells (261 ± 46%). We determined the number of incorporated Y chromosome-positive cells derived from the male CathL-deficient donor mice by fluorescence in situ hybridization Fig. 12 online) . The vascular incorporation of Ctsl -/-cells was significantly (P < 0.05) reduced to 45.5 ± 9.2% relative to wild-type cells. To ascertain if the effect of CathL was specific, by comparison to other proteases, we next infused cells from MMP-9-or CathD-deficient (Ctsd -/-mice using the same nude mouse model of hind limb ischemia. Neither Ctsd -/-nor Mmp9 -/-bone marrow-derived cells showed reduced neovascularization capacity as compared to wild-type cells (Fig. 5g) . These data suggest that the lack of CathL specifically impairs the functional incorporation of bone marrow-derived progenitor cells, which may account for the impaired neovascularization capacity of Ctsl -/-mice. Indeed, the reduced neovascularization of Ctsl -/-mice was at least partially reversed by infusion of wild-type cells (Fig. 5h) . Finally, we determined the contribution of bone marrow-derived circulating progenitor cells to the increased protease activity found in ischemic tissues in vivo. For this purpose, mice were lethally irradiated to ablate the bone marrow before the induction of hind limb ischemia. Forty-eight hours after induction of ischemia, muscle lysates of the ischemic and nonischemic limbs were analyzed by zymography and western blot. As shown in Supplementary Fig. 13 online, CathL and MMP-9 activities were significantly (P < 0.05) induced in ischemic tissue. In irradiated mice, MMP-9 activity was still significantly (P < 0.05) upregulated after ischemia (Supplementary Fig. 13 online) , indicating that MMP-9 activity is increased independent of bone marrow-derived cells and hence is likely generated by cells that reside in the tissue. In contrast, ischemia-induced augmentation of CathL activity was abolished in irradiated mice (Supplementary Fig. 13 online) , showing that the increase of CathL activity in ischemic tissue is mediated by irradiationsensitive cells that probably originate from the bone marrow.
CathL improves neovascularization capacity of HUVEC
To investigate whether ectopic expression of CathL in mature endothelial cells might suffice to generate cells that are capable of promoting neovascularization after intravenous infusion, HUVEC were transiently transfected with CathL prior to injection into nude mice after induction of ischemia. The infusion of CathL-transfected HUVEC significantly (P < 0.05) increased the recovery of limb perfusion as compared to vectortransfected cells (Fig. 6a) . Control experiments confirmed that transfection of HUVEC with CathL resulted in an increased CathL expression and activity (Fig. 6b,c) and subsequently enhanced their invasive capacity in vitro (Fig. 6d) . Likewise, infusion of isolated mature aortic endothelial cells from transgenic mice expressing CathL also improved neovascularization following hind limb ischemia (135 ± 16% of control; n = 3). In contrast, transient expression of a nonsecretable CathL mutant 20 did not improve neovascularization of HUVEC (Fig. 6a) . 
DISCUSSION
Proteases are of major importance for the formation of new blood vessels [21] [22] [23] . In order to form sprouts, endothelial cells must penetrate the extracellular matrix, which consists of type IV collagen, laminin, fibronectin and many other macromolecules. For this purpose, mature endothelial cells are equipped with a set of proteases including MMPs and the urokinase-type plasminogen activator. Notably, our study indicates that circulating progenitor cells express a distinct pattern of proteases. Ex vivo cultivated peripheral blood-derived EPC showed profoundly increased levels of cathepsins as compared to mature endothelial cells, monocytes and lymphocytes. These broad-spectrum proteases are potent in degrading several extracellular matrix proteins such as laminin, fibronectin, collagens I and IV, elastin and other structural proteins of basement membranes (reviewed in refs. 24, 25) . Notably, EPC secrete large amounts of CathL and the extracellular matrix-degrading activity of EPC toward gelatin or collagen is abolished by pharmacological inhibition or genetic ablation of CathL. Given the overlapping substrate specificity of lysosomal proteases, it is notable that CathL seems to be of particular importance for EPC invasion. Previous studies using CathL knockout animals provide evidence for biological effects being specifically mediated by CathL 26, 27 . In line with these findings, our results show that the recovery from hind limb ischemia is substantially impaired in Ctsl -/-mice. Moreover, pharmacological inhibition of CathL abolished the matrix-degrading activity of EPC extracts or cell culture supernatants. CathS was recently shown to contribute to angiogenesis 28 . In our experiments, however, pharmacological inhibition of CathS did not affect EPC invasion. Moreover, genetic ablation of another related member of the cathepsin family, CathD, did not reduce the ability of bone marrow-derived stem cells to promote neovascularization following ischemia. Moreover, pharmacological inhibition of other proteases such as elastases or MMPs did not affect the invasive activity of EPC in vitro. In line with these in vitro findings, MMP-9-deficient progenitor cells showed no impaired ability to augment neovascularization in vivo. Likewise, the increase of MMP-9 activity after induction of ischemia was independent of bone marrow-derived cells, but rather reflects an increased local release by cells that reside in the tissues. In contrast, the observed upregulation of CathL following ischemia was abolished by irradiation-induced bone marrow ablation. Thus, our data indicate that CathL has a specific and crucial role, as opposed to other cathepsins or MMP-9, for EPC function in neovascularization.
The impairment of neovascularization in Ctsl -/-mice may be related to a reduction in functional activity of mature endothelial cells from Ctsl -/-mice resulting in impaired angiogenesis or a reduced capacity of EPC to promote vasculogenesis. Because we showed that pharmacological CathL inhibitors and genetic depletion of CathL did not affect the proangiogenic activity of mature endothelial cells, interference with the classical angiogenesis pathway by blocking or deleting CathL seems unlikely. In contrast, CathL may contribute to vasculogenesis specifically by promoting the invasive activity of EPC, as opposed to EPC mobilization, adhesion, survival or migration. Inhibition or genetic ablation of CathL specifically reduced the invasive potential of EPC in vitro. Moreover, inhibition of CathL blocked the invasion and incorporation of EPC into tumor capillaries in vivo and reduced the incorporation and functional activity of EPC in the hind limb ischemia model. But the finding that most of our studies show only partial inhibition of neovascularization by pharmacological or genetic depletion of CathL indicates that other proteases or adhesion molecules support the incorporation of EPC into the ischemic limbs.
Taken together, the present findings show a critical role for CathL in the invasive and functional capacity of EPC. The high expression levels of CathL in EPC equip these cells for 'drilling for oxygen' to promote blood supply to ischemic tissues. In contrast, inhibition of the invasive potential of circulating progenitor cells by CathL inhibitors may be an attractive target for limiting tumor vascularization, which is critically dependent on EPC invasion 29, 30 .
METHODS
Generation of CathL-deficient mice and transgenic mice overexpressing human CathL. CathL-deficient mice were generated by gene targeting in mouse embryonic stem cells as described 31, 32 . Expression of Ctsl mRNA, CathL protein and activity was completely abolished in CathL-deficient mice 32 . CathL-transgenic mice were generated as previously described 33 . CathD-and MMP-9-deficient mice have been generated as described 34, 35 .
Plasmid transfection. A plasmid encoding human full length pro-CathL was cloned by PCR from cDNA of EPC into pcDNA3.1-Myc-His (Invitrogen). We cloned a plasmid encoding the nonsecretable human pro-CathL delta TV mutant lacking the last two carboxy-terminal amino acids by PCR from full-length pro-CathL into pcDNA3.1-Myc-His as previously described 20 . We performed transient transfection of HUVEC (24 h) as described previously 36 .
In vitro invasion. A modified Boyden chamber (Transwell, 8 µm pore size, BD Falcon) was filled with Matrigel (4 mg/ml; BD Biosciences). We placed detached cells (10 5 
Confocal proteolysis assay.
In vivo proteolysis as previously described 37 was modified as follows: one half of a plastic ring was filled with 100 µl Matrigel (10 mg/ml, BD Biosciences) containing the quenched fluorescent substrate DQ gelatin (25 µg/ml, Molecular Probes) in the presence of VEGF (50 ng/ml) and SDF-1 (50 ng/ml). The other half of the ring was filled with 100 µl Matrigel (10 mg/ml) containing 1 × 10 5 CM-Dil-labeled cells. After incubation for 12 h at 37 °C, the proteolytic activity (green fluorescence) was determined by confocal microscopy using a LSM 510.
Zymography. We concentrated cell culture supernatants (10 times) using Ultrafree-4 centrifugal filter tubes with Biomax-5 membrane (Millipore). We lysed cells in buffer (1% Triton-X-100, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 1 mM PMSF, 20 mM Tris (pH 7.4), 2.5 mM Na-pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na-orthovanadate, 1 µg/ml leupeptin). We analyzed metalloproteinase activity by gelatinolytic zymography as described 38 . The gelatin and collagen zymography for acidic proteases was performed according to previous studies 39 . After gel electrophoresis, the gels were washed twice for 20 min with 25% isopropanol to remove sodium dodecyl sulfate 40 .
Mouse model of hind limb ischemia. This study was performed with permission of the State of Hesse, Regierungspraesidium Darmstadt, according to section 8 of the German Law for the Protection of Animals and conforms to the Guide for the Care and Use of Laboratory Animals measurements. The mouse model of hind limb ischemia was performed by use of 8-10-week-old athymic NMRI nude mice (Charles River) or as indicated. We ligated the proximal femoral artery including the superficial and the deep branch as well as the distal saphenous artery. We injected cells intravenously 24 h after induction of unilateral hind limb ischemia. Animals received untreated human EPC and pretreated EPC (Z-FF-FMK; 10 µM; 2 h) or sex-mismatched bone marrow cells from male CathL-deficient and wild-type mice, respectively. We harvested bone marrow aseptically by flushing tibias and femurs of donor mice, filtered it (100 µm) and isolated mononuclear cells by density gradient centrifugation. The use of human cells was approved by the Ethics Committee of the University of Frankfurt.
Limb perfusion. After 2 weeks, we measured the ratio of blood flow in the ischemic (right) to normal (left) limb with a laser Doppler blood flow meter (MoorLDI-Mark 2, Moor Instruments, Inc.). After recording laser Doppler color images, we calculated the average perfusions of the ischemic and non-ischemic limb on the basis of colored histogram pixels.
EPC tracking by magnetic resonance imaging (MRI)
. EPC were labeled with 0.9 µm superparamagnetic divinyl benzene inert polymer microspheres (Bangs Laboratories) 41 and intravenously injected 24 h after induction of ischemia.
After another 24 h, we placed mice inside a small loop coil on a 1.5-Tesla system (Magnetom Sonata, Siemens). We performed two-dimensional MRI using turbo inversion recovery magnitude sequences to visualize the edema related to the ischemia and T2*-weighted gradient echo sequences to visualize the magnetic field distortion related to the presence of superparamagnetic particles-labeled EPC.
Histological evaluation. Capillary density was determined in 8-µm frozen sections of the adductor and semimembraneous muscles. Endothelial cells were stained for CD146 (Chemicon) or CD31 (BD Biosciences), respectively. Capillary density is expressed as number of capillaries per myocyte. We identified human EPC by costaining for HLA-A, HLA-B and HLA-C (APC-labeled; BD Biosciences).
Statistical analysis.
Results for continuous variables are expressed as mean ± s.e.m. or as stated otherwise. Comparisons between groups were analyzed by t-test (twosided) or ANOVA for experiments with more than two subgroups. Post hoc range tests and pairwise multiple comparisons were performed with t-test (two-sided) with Bonferroni adjustment. P < 0.05 was considered statistically significant. All analyses were performed with SPSS 11.5 software (SPSS Inc.).
Accession number. Microarray data from this study are available in the Gene Expression Omnibus using the accession number GSE2040.
Note: Supplementary information is available on the Nature Medicine website.
